Aarkstore announce a new report "The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis " through its vast collection of market research report.
Analysis of the leading therapeutic segments including diabetes and obesity.
• Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of drug development
• Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
• Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to
• Align product portfolio to the markets with high growth potential
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
• Develop key strategic initiatives by understanding key focus areas of leading companies
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
For more information, please visit:
http://www.aarkstore.com/reports/The-Future-of-Metabolic-Disorder-Therapeutics-M Or email us at press@aarkstore.com or call +919272852585
Analysis of the leading therapeutic segments including diabetes and obesity.
• Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
• Key drivers and barriers that have a significant impact on the market
• Coverage of pipeline molecules in various phases of drug development
• Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
• Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
• Align product portfolio to the markets with high growth potential
• Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
• Develop key strategic initiatives by understanding key focus areas of leading companies
• Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
For more information, please visit:
http://www.aarkstore.com/reports/The-Future-of-Metabolic-Disorder-Therapeutics-M
Or email us at press@aarkstore.com or call +919272852585